MicroRNA-155 deficiency attenuates inflammation and oxidative stress in experimental autoimmune prostatitis in a

Xian Fu1, Hua-Dong He1, Chang-Jiu Li2

  • 1Department of Urology, Affiliated Hangzhou First People's Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.

Insights

MicroRNA-155 deficiency protects against experimental autoimmune prostatitis by reducing inflammation and oxidative stress via the toll-like receptor 4 pathway. This suggests a potential therapeutic strategy for chronic prostatitis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Urology

Background:

  • Experimental autoimmune prostatitis (EAP) is an inflammatory condition.
  • MicroRNA-155 (miR-155) role in inflammation is complex and requires further elucidation.
  • Toll-like receptor 4 (TLR4) signaling is implicated in inflammatory processes.

Purpose of the Study:

  • To investigate the protective mechanism of miR-155 deficiency in EAP.
  • To determine the involvement of the TLR4 pathway in miR-155's protective effects.
  • To explore the therapeutic potential of modulating miR-155 in chronic prostatitis.

Main Methods:

  • EAP model established in wild-type (WT) and miR-155 knockout (miR-155-/-) mice.
  • Administration of lipopolysaccharide (LPS) to assess TLR4 ligand effects.
  • Assessment of pain (von Frey filaments), inflammation (HE staining), gene/protein expression (qRT-PCR, Western blotting, ELISA), and oxidative stress markers (SOD, GSH-Px, MDA).

Main Results:

  • miR-155-/- mice with EAP showed reduced pain, inflammation, and suppressed TLR4/NF-κB pathway activation compared to WT mice.
  • LPS treatment upregulated miR-155 and activated the TLR4/NF-κB pathway in WT mice with EAP.
  • miR-155 deficiency decreased pro-inflammatory cytokines (IL-1β, TNF-α, IL-6, IFN-γ, IL-12) and MDA, while increasing anti-inflammatory IL-10, SOD, and GSH-Px.

Conclusions:

  • miR-155 deficiency ameliorates pain and reduces inflammation and oxidative stress in EAP.
  • The protective effect is mediated through the TLR4/NF-κB signaling pathway.
  • Targeting miR-155 offers a potential therapeutic strategy for chronic prostatitis.